Infinity Pharmaceuticals, Inc.

2:45 PM - 3:00 PM, Tuesday, June 4, 2019 ・ Theater 2
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing.
Ticker:
INFI
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2001
Main Therapeutic Focus:
Lead Product in Development:
IPI-549
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Chair and CEO
Infinity Pharmaceuticals, Inc.